Research
Peanut Peptide Injections Promising for Allergy Immunotherapy
The Brief
- A novel peptide-based immunotherapy for peanut allergy appeared safe in a phase II trial.
- In children, it modestly reduced symptoms over the first 12 months, according to the trial results reported.
- The source excerpt does not give the efficacy figures, trial size or comparator details.
Why it matters
Peanut allergy has few treatment options, so an immunotherapy that appears safe and modestly effective in children is worth tracking through later-stage trials.
Who’s affected
- allergists and clinicians who treat food allergy
- families of children with peanut allergy
(MedPage Today) -- A novel peptide-based immunotherapy for peanut allergy appeared safe and modestly efficacious for reducing children's symptoms over the first 12 months, a phase II trial showed. For the primary efficacy endpoint, the higher...